project id: TCGA-BLCA; case submitter id: TCGA-DK-A3IM; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.82; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.8; rna integrity number: 7.6; age at index: 76; days to birth: -28106; days to death: 248; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Dead; year of birth: 1935; age at diagnosis: 28106; ajcc pathologic m: M0; ajcc pathologic n: N0; ajcc pathologic stage: Stage III; ajcc pathologic t: T3; ajcc staging system edition: 6th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 238.0; icd 10 code: C67.9; last known disease status: not reported; morphology: 8120/3; primary diagnosis: Transitional cell carcinoma; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Bladder, NOS; synchronous malignancy: No; tissue or organ of origin: Bladder, NOS; tumor grade: Not Reported; year of diagnosis: 2011; treatment or therapy: not reported; alcohol history: Not Reported; cigarettes per day: 0.4383561643835616; pack years smoked: 8.0; is ffpe: false; composition: Not Reported; days to collection: 254; days to sample procurement: 0; initial weight: 480.0; portion submitter id: TCGA-DK-A3IM-01A-11; percent lymphocyte infiltration: 1.0; percent monocyte infiltration: 1.0; percent necrosis: 20.0; percent neutrophil infiltration: 2.0; percent normal cells: 5.0; percent stromal cells: 0.0; percent tumor cells: 75.0; percent tumor nuclei: 85.0;